利妥昔单抗成功治疗新型冠状病毒肺炎感染后皮肌炎发作：一例报告及文献综述
Dermatomyositis Flare After a COVID-19 Infection Successfully Treated with Rituximab: A Case Report and Literature Review.
作者信息
Albakri Ahmed Mohammed, Subki Ahmed Hussein, Albeity Abdurahman, Halabi Hussein
机构信息
Department of Medicine, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.
出版信息
J Inflamm Res. 2022 Nov 2;15:6047-6053. doi: 10.2147/JIR.S369477. eCollection 2022.
INTRODUCTION
Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic, there has been a sudden surge in the incidence of several immune-mediated diseases, including dermatomyositis. The reported cases of COVID-19-related dermatomyositis are heterogeneous in their clinical presentation and implemented therapies.
CASE STUDY
We report a 23-year-old female patient diagnosed with a 3-year history of dermatomyositis. She has been well-controlled on maintenance therapy. However, 6 weeks after a mild COVID-19 infection, she developed a dermatomyositis flare. She improved only after aggressive treatment with pulse steroids, intravenous immunoglobulin, and rituximab.
CONCLUSION
Exacerbation of dermatomyositis can be encountered following a COVID-19 infection, even if the infection is mild. Aggressive therapy should be considered in such cases. The prognosis, however, is generally favorable.
引言
自2019年冠状病毒病（COVID-19）大流行开始以来，包括皮肌炎在内的几种免疫介导疾病的发病率突然激增。报告的与COVID-19相关的皮肌炎病例在临床表现和实施的治疗方法上存在异质性。
病例研究
我们报告一名23岁女性患者，诊断为患有3年皮肌炎病史。她一直通过维持治疗得到良好控制。然而，在轻度COVID-19感染6周后，她出现了皮肌炎发作。仅在接受脉冲类固醇、静脉注射免疫球蛋白和利妥昔单抗的积极治疗后，她才有所改善。
结论
即使感染较轻，COVID-19感染后也可能出现皮肌炎加重。在这种情况下应考虑积极治疗。然而，总体预后良好。
Zotero 插件